Mizuho raised the firm’s price target on Wave Life Sciences (WVE) to $22 from $19 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. The firm says Wave Life remains a potential secular growth story for 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE: